Skip to content
Forge Biologics
  • About
    • About
    • Mission & Approach
    • Leadership
    • Board
  • Services
    • Manufacturing Services
    • Technology
  • Science
    • Science
    • Pipeline
    • About Gene Therapy
    • FBX-101 for Krabbe Disease
  • Careers
  • News & Insights
    • News
    • Events
    • Insights
    • Media Kit
  • Connect

Gene therapy company secures largest series B financing in Ohio’s history

Posted on April 29, 2021 (July 13, 2021) by K Terry Smith
0/5 (0 Reviews)
Posted in Biologics News, In the news, Krabbe DiseaseTagged IND, investigational new drug application

Post navigation

 Drive-backed gene therapy startup raises $120M to amp up biotech manufacturing in Grove CityFour Biotechs Rake in Over $350 Million for Rare Diseases, Cancers and More 
Copyright Forge Biologics - All Rights Reserved Cookie Notice | Privacy Policy

I agree to the Cookie Notice and Privacy Policy

I agree